Genetic Technologies Profit Margin

Genetic Technologies (GENE) currently reports a profit margin of -147.04% as of June 2024. That compares with -103.65% in the prior-year period — down 41.9% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Genetic Technologies's profit margin history and peer comparisons.

Genetic Technologies's profit margin decreased from -103.65% to -147.04% — a 41.9% year-over-year decrease (period ending June 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Genetic Technologies's profit margin of -147.04% is lower than the Healthcare sector average of 13.89%. That is roughly 1158.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Genetic Technologies's current -147.04% should be judged against Healthcare norms (sector average: 13.89%) and against GENE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -147.04%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Genetic Technologies, and consider following GENE for alerts when major investors trade the stock.